Recent News

• 06.09.2026 - Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
• 05.19.2026 - Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
• 05.11.2026 - Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
• 05.07.2026 - Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
• 04.30.2026 - Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

Recent Filings

• 06.04.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.04.2026 - EX-99.1 EX-99.1
• 06.03.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.03.2026 - EX-99.1 EX-99.1
• 05.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.29.2026 - EX-99.1 EX-99.1
• 05.19.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.19.2026 - EX-99.1 EX-99.1
• 05.12.2026 - EX-99.1 EX-99.1
• 05.12.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]